Zimmer Biomet Stock (NYSE:ZBH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$93.73

52W Range

$84.59 - $114.44

50D Avg

$92.28

200D Avg

$95.28

Market Cap

$18.35B

Avg Vol (3M)

$2.20M

Beta

0.59

Div Yield

$0.96 (1.04%)

ZBH Company Profile


Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

17,000

IPO Date

Jul 25, 2001

Website

ZBH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
S E T$2.15B$1.87B$1.75B
Hips$2.09B$2.00B$1.97B
Knees$3.32B$3.17B$3.04B
Other Product Category-$640.30M$636.00M

Fiscal year ends in Dec 25 | Currency in USD

ZBH Financial Summary


Dec 25Dec 24Dec 23
Revenue$8.23B$7.68B$7.39B
Operating Income$1.36B$1.29B$1.28B
Net Income$705.20M$903.80M$1.02B
EBITDA$2.22B$2.25B$2.22B
Basic EPS$3.56$4.45$4.91
Diluted EPS$3.55$4.43$4.88

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 10, 26 | 8:30 AM
Q3 25Nov 05, 25 | 8:30 AM
Q2 25Aug 07, 25 | 8:30 AM

Peer Comparison


TickerCompany
WATWaters Corporation
SNNSmith & Nephew plc
INCYIncyte Corporation
WSTWest Pharmaceutical Services, Inc.
DGXQuest Diagnostics Incorporated
LHLabcorp Holdings Inc.
STESTERIS plc
ILMNIllumina, Inc.
DXCMDexCom, Inc.
UTHRUnited Therapeutics Corporation